Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9793858 | 1.00 | BLM (0.35) | BLMPOLBMEN1KMT2APRSS1 | |
| SCHEMBL6137571 | 0.85 | MAOB (0.40) | KDM4E | |
| SCHEMBL6137564 | 0.85 | MAOB (0.40) | KDM4E | |
| SCHEMBL18029421 | 0.84 | MEN1 (0.35) | BLMPOLBMEN1KMT2APRSS1 | |
| SCHEMBL14588832 | 0.84 | PYCR1 (0.37) | — | |
| SCHEMBL11291951 | 0.82 | — | — | |
| SCHEMBL2493373 | 0.79 | POLB (0.36) | POLBMEN1KMT2AKDM4E | |
| SCHEMBL10546047 | 0.78 | ABCB1 (0.39) | BLMPOLBMEN1KMT2APRSS1 | |
| SCHEMBL14588797 | 0.77 | AGXT (0.42) | — | |
| SCHEMBL6137281 | 0.77 | CYP2D6 (0.42) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864308-B1 | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues | UNIV BRISTOL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150158837-A1 | Compound And Method | TOPOKINE THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158837-A1 | Compound And Method | TOPOKINE THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8476471-B2 | Synthesis of prostanoids | IRIX PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120165293-A1 | SYNTHESIS OF PROSTANOIDS | PATHEON API SERVICES INC. | 2012-06-28 | — | — | US | disclosed |
| US-6482990-B1 | Prostaglandin E analogues | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| EP-1211241-A1 | PROSTAGLANDIN E ANALOGUES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2002-06-05 | — | — | EP | disclosed |
| EP-0255098-B1 | Novel 8-(lower alkyl) bicyclo [4.2.0] octane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4983627-A | Treating atherosclerosis, thrombosis and vasospasms; anticholesterol,-secretory,-ulcer and hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0196617-B1 | [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same | SYNTEX (U.S.A.) INC. (US) | 1989-05-31 | — | — | EP | disclosed |
| US-4735966-A | ANTICOAGULANTS, VASODILATORS, HYPOTENSIVE AND ANTICHOLESTEROL AGENTS | SYNTEX (U.S.A.) INC. (US) | 1988-04-05 | — | — | US | disclosed |
| EP-0257609-A2 | Novel substituted (4.2.0)Bicyclooctane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1988-03-02 | — | — | EP | disclosed |
| EP-0255098-A1 | Novel 8-(lower alkyl) bicyclo [4.2.0] octane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1988-02-03 | — | — | EP | disclosed |
| US-4678805-A | Novel 8-(lower alkyl)bicyclo[4.2.0]octane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1987-07-07 | — | — | US | disclosed |
| EP-0196617-A1 | [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same | SYNTEX (U.S.A.) INC. (US) | 1986-10-08 | — | — | EP | disclosed |
| US-4608388-A | Novel [4,2,0]bicyclooctane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1986-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165293-A1 | SYNTHESIS OF PROSTANOIDS | PTGIS, PTGES, PTGS2 | BLM 1608/4885POLB 1465/4885MEN1 1238/4885 |
| US-20150158837-A1 | Compound And Method | CYP4A11, NR1H2, NR1H3 | BLM 4434/4885POLB 3618/4885MEN1 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.